BroadOak Capital Partners

Since 2006, we have helped life sciences businesses achieve their full potential

BroadOak Capital Partners is a life sciences focused, boutique financial institution that provides direct investment through BroadOak Asset Management, and investment banking services through BroadOak Partners, to companies in the life sciences tools, diagnostics, and biopharma services sectors BroadOak has made investments in more than 50 companies and advised on over 50 successful M&A transactions

Growth capital for the development and acceleration of successful businesses

Services to help management teams optimize sale processes, mergers, acquisitions, and financing

BroadOak advises and invests in life sciences tools, diagnostics, and services companies Each sector is highly specialized, and most traditional financial institutions do not have the experience or expertise necessary to provide a true partnership BroadOak is different Our in-house expertise, access to proprietary information via deep relationships and networks, and reputation built on 15 years of experience give our portfolio companies and clients results that exceed expectations

Instruments and consumables used in therapeutic discovery and development Diagnostic tests, test components, and instruments for analysis Research, development, and manufacturing services for biopharma companies

Recent Investments & Advisory Transactions

Sanguine Biosciences Partners with BroadOak

Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine and cell

BroadOak Invests in CDI Laboratories

BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation

PBS Biotech Raises $22M

BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million financing that